The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2009Assessment of the Therapeutic Efficacy of Progranulin in a Sub-chronic Small Model of Parkinson's Disease
Objective/Rationale:
Progranulin (PGRN), a protein found in the brain, is thought to promote the survival and health of brain cells. Neurodyn Inc. has discovered PGRN to have disease-modifying effects... -
Therapeutics Development Initiative, 2009Optimising Lead Series of Small Molecule Inhibitors of LRRK2 to Deliver Tool Compounds and Clinical Development Candidates
Objective/Rationale:
The exciting discovery of activating mutations in the LRRK2 kinase in a subset of familial PD patients provides a route to better understanding of signaling pathways that, when... -
Rapid Response Innovation Awards, 2009Uncovering Factors that Prevent Dopaminergic Neuronal Degeneration in a Novel C. elegans Model for Parkinson's Disease using a High-throughput Forward Genetics Approach
Objective/Rationale:
Our inability to slow down the progression of Parkinson’s disease (PD) reflects our incomplete knowledge of the molecular mechanisms that cause the selective death of dopaminergic... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2009Optimization of Alpha-synuclein 5'UTR Directed Translation Blockers as Novel Drugs for Parkinson's Disease
Objective/Rationale:
Posiphen is a well-tolerated translation blocker of the Parkinson’s disease causative protein alpha-synuclein (SNCA) via the 5’untranslated region (5’UTR) in its mRNA. Our goal is... -
Biomarkers, 2009Analysis of the Enteric Nervous System Using Routine Colonic Biopsies: A Biomarker of Neurodegeneration in Parkinson's Disease
Objective/Rationale:
The “core” of the neuronal lesions of Parkinson’s disease (PD) is the progressive degeneration of dopamine neurons in the central nervous system (CNS). It is now well established... -
Biomarkers, 2009Development of an mGluR5 Imaging Marker for Parkinson's Disease
Objective/Rationale:
The goal of this proposal is to develop an imaging test, 18F-PEB PET, to assess glutamate function in the brain of individuals with Parkinson disease (PD) and determine if the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.